ANI Pharmaceuticals, Inc. (ANIP) vs Xeris Biopharma Holdings, Inc. (XERS)
- ANI Pharmaceuticals, Inc. ANIP 72.08 −0.28%
- Xeris Biopharma Holdings, Inc. XERS 10.28 +2.09%
ANI Pharmaceuticals, Inc. and Xeris Biopharma Holdings, Inc. are both Drug Manufacturers Specialty & Generic companies. Xeris Biopharma Holdings, Inc. is the larger, with a market value of $1.8B against $1.7B — 1.1× the size. Xeris Biopharma Holdings, Inc. has negative trailing earnings, so its P/E is not meaningful; ANI Pharmaceuticals, Inc. trades at 14.9×. Xeris Biopharma Holdings, Inc. grew revenue faster over the last twelve months: 36.3% against 30.9%. ANI Pharmaceuticals, Inc. has the higher net margin (11.0% vs −5.12%) and the lower return on invested capital (11.3% vs 18.9%). Across the 19 metrics below, ANI Pharmaceuticals, Inc. leads on 13 and Xeris Biopharma Holdings, Inc. on 6.
Valuation
Profitability
| Metric | ANIP | XERS | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 60.40% | 86.58% | 53.94% |
| Operating margin | 15.37% | 10.91% | 0.00% |
| Net margin | 11.04% | (5.12%) | 0.00% |
| Free cash flow margin | 17.12% | 16.60% | 0.00% |
| Return on equity | 20.88% | 118.22% | (0.40%) |
| Return on assets | 7.61% | (4.60%) | (3.32%) |
| Return on invested capital | 11.30% | 18.88% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack